Telepsychology-Service Delivery for Depressed Elderly Veterans: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Telepsychology-Service Delivery for Depressed Elderly Veterans (NCT00324701), a randomized na study. The primary outcome is At Least a 50% Improvement From Baseline to Post-treatment on the Geriatric Depression Scale (GDS).

2. Clinical Question

The study's stated purpose was to assess whether therapy for elderly adults with major depression could be delivered using videoconferencing, and whether this delivery approach was an acceptable alternative to traditional therapy with the therapist and patient in the same room. The registry record identifies the comparison and endpoint but does not provide outcome estimates that answer the comparative question. Its entry indicates that the primary outcome has several categories or time points and was not reduced to one comparison. Therefore, the record does not establish whether response proportions were similar, different, higher, or lower between the approaches.

3. Trial Design

The registry describes a randomized, parallel-group trial with no masking. Participants were assigned to telepsychology or face-to-face therapy. The recorded enrollment is 241. The adverse-event group records list 120 participants at risk in the telepsychology group and 121 in the face-to-face therapy group. The record does not provide additional allocation details, such as the sequence-generation or concealment procedures.

Telepsychology was described as therapy done at patients' houses; face-to-face therapy was delivered at the VAMC. These descriptions indicate that the comparison concerns service delivery as well as the location in which therapy took place. The registry does not specify enough about session content, therapist assignment, treatment fidelity, or the amount of therapy to characterize whether other aspects of treatment were held constant.

The record lists the study status as completed, with a start date of 2006-09 and primary completion in 2011-07. The sponsor is the US Department of Veterans Affairs. The phase entry is NA. No further details about recruitment, follow-up procedures, or trial conduct are reported in the registry record.

Random allocation is intended, in general, to create groups that are comparable on average at the start of a study. A parallel design assigns participants to one group for the comparison rather than describing a sequence in which each participant receives both approaches. With no masking, participants and treatment providers were not masked to the assigned service-delivery approach; whether outcome assessors were masked is not reported in the registry record. These design details alone do not establish the quality of implementation or the validity of an outcome comparison.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Participants completing 8 week and 12 month assessments.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Older adult Veterans (age 60 or older) presenting for services at VA primary care clinics and meeting DSM-IV criteria for major depressive disorder.

6. Primary Endpoint

The registry lists the primary outcome as At Least a 50% Improvement From Baseline to Post-treatment on the Geriatric Depression Scale (GDS), measured over 8 week & 12 months.

The primary endpoint is the percentage of participants with at least a 50% improvement from baseline to post-treatment on the Geriatric Depression Scale (GDS). It is a binary response measure: a participant either meets the specified improvement threshold or does not. The registry lists the timeframe as 8 week & 12 months and describes the population as participants completing those assessments.

The GDS is described as a 30-item self-report assessment designed to identify depression in elderly people. Participants answer yes or no with reference to how they felt over the past week, and higher scores indicate more severe depression. Expressing change as a response threshold can make a clinical outcome easier to summarize as the proportion meeting a prespecified level of improvement. It also discards information: participants just below and well below the threshold are both counted as nonresponders, while different degrees of improvement above the threshold are grouped as responders.

The registry record does not explain why this threshold was selected, how baseline and post-treatment scores were handled, or whether the same endpoint definition was used at each listed follow-up. The record lists the outcome but does not provide response counts, percentages, or confidence-interval values. Thus the endpoint's definition can be described, but its observed result cannot be interpreted from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does randomization contribute?

In general, randomization assigns participants to study groups by chance. Its purpose is to reduce systematic differences between groups at the start of a trial, including differences that investigators may not have measured. It does not guarantee identical groups, and it cannot by itself prevent bias from unequal follow-up, deviations from assigned treatment, or selective outcome reporting. The record calls this study randomized, but the sequence-generation and allocation-concealment methods are not reported in the registry record.

A parallel design compares groups assigned to different approaches over the study rather than comparing each participant with themself under both approaches. The registry describes the trial as parallel and lists telepsychology and face-to-face therapy as its arms. Because masking is recorded as none, participants and people delivering therapy would know which approach was assigned. The registry does not report whether outcome assessment or data analysis was masked. Lack of masking can matter when outcomes involve self-report, expectations, or decisions about how to collect and classify information, but the record does not establish whether such influences affected this trial.

How should a binary response endpoint be understood?

The primary outcome is a binary response indicator based on whether GDS improvement reaches at least a 50% threshold from baseline to post-treatment. A binary endpoint is commonly summarized as a proportion or percentage meeting the definition in each group. A comparison may then describe the difference between those proportions, with uncertainty around the estimate. The registry specifies the endpoint unit as percentage of participants with treatment response, but provides no group percentages or comparison estimates.

Turning a scale into a responder/nonresponder outcome can aid communication, because the result has a direct threshold-based interpretation. The trade-off is loss of detail: a participant's exact score change no longer appears in the binary classification. The threshold also makes the result dependent on its definition. The registry gives the threshold but does not report its rationale or details of score handling. The GDS itself is described as a 30-item yes/no self-report measure about the past week, with higher scores indicating more severe depression.

What does a confidence interval add?

In general, a confidence interval expresses the statistical uncertainty around an estimated quantity, such as a response proportion or a contrast between groups. It provides a range of values compatible with the data and the assumptions of the method. It should be interpreted alongside the estimate and study design; it is not a guarantee that the true value lies inside a particular interval. A narrow interval generally indicates greater precision than a wide interval, but precision does not establish that an effect is important.

The registry identifies a 95% Confidence Interval as the primary outcome's dispersion measure. It does not provide the confidence-interval endpoints, the response estimates, or the method used to calculate them. No interval width or statistical significance can be inferred from the endpoint description alone. The 95% label should not be mistaken for a reported result when the actual interval values are absent.

Why do follow-up times and completeness matter?

The primary endpoint lists 8 week & 12 months, and its stated population comprises participants completing those assessments. When an outcome is recorded at more than one follow-up, analyses may treat each time separately or use a model that accounts for repeated observations. These approaches answer different questions and make different assumptions about the relationship between measurements from the same participant. The registry does not report which approach was used; it notes that the outcome has several categories or time points and was not reduced to one comparison.

Missing outcome data also affect interpretation. In general, a percentage among participants with completed assessments describes the observed participants included in that calculation, not automatically every randomized participant. If people with missing assessments differ in outcome from people with observed assessments, a complete-case estimate may not represent the full randomized groups. This is a general concern, not a claim about what happened in this trial. The registry does not report missing-data counts, reasons for missingness, imputation, sensitivity analyses, or the exact analysis population.

What statistical analysis is documented?

The registry records 0 analyses and does not describe a statistical analysis plan, an adjusted model, or an approach to multiplicity. It therefore cannot support claims about which inferential procedure was used or whether any assumptions were checked. For a binary outcome, general analysis options include estimating group response proportions and comparing them with an appropriate method. If observations are repeated across follow-up times, the analysis may also need to account for their dependence. These are general methodological considerations, not methods confirmed for this trial.

The registry includes planning assumptions for sample-size illustrations: a two-sided significance level of 0.05, equal allocation, and a normal approximation, with effects defined as fractions of an observed effect. Such illustrations are planning aids, not observed power and not proof that the trial was designed using those assumptions. The registry does not report the trial's own sample-size justification. Since the primary comparison is not reported in the registry record, the observed effect underlying any planning illustration cannot be evaluated from this entry.

10. Multiplicity, Missing Data and Analysis Populations

The primary endpoint is listed at 8 week & 12 months, and the registry notes that the outcome has several categories or time points and was not reduced to one comparison. When a study examines more than one outcome, time point, subgroup, or analysis, the chance of finding at least one apparently notable result can increase if each is treated as a separate test. General approaches to this issue include identifying a primary comparison in advance, adjusting for multiple testing, or interpreting results as exploratory. The registry record does not report a multiplicity strategy, planned testing hierarchy, or analysis plan, so it is not possible to tell how multiple time points or outcomes were handled.

The record describes the primary-outcome population as participants completing the 8 week and 12 month assessments. It does not report how many participants completed each assessment, how missing values were handled, or whether the analysis followed randomized assignment regardless of treatment received. These details matter because an analysis restricted to people with observed outcomes can differ from one that includes all randomized participants under a stated missing-data approach. No particular missing-data method should be assumed.

SCID: Structured Clinical Interview for the DSM-IV is listed as a secondary outcome. The registry lists 2 outcome measures and 0 analyses but gives no results for the primary or secondary measure. Without the analysis plan and outcome results, the record does not establish whether the reported outcomes were selectively presented or how any multiple comparisons were interpreted. These items are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry lists serious adverse events and other adverse events by group. For telepsychology, the record lists 120 participants at risk, 0 with a serious adverse event, and 0 with another adverse event. For face-to-face therapy, it lists 121 participants at risk, 0 with a serious adverse event, and 0 with another adverse event. The deaths entries are null for both groups; null does not establish that the count was zero.

These figures should be read as the registry's recorded counts for the categories shown, not as a complete account of every possible safety outcome. The record does not provide event definitions, observation duration for adverse events, severity details beyond the serious-event category, attribution to therapy, or information about ascertainment procedures. It lists no top serious-event terms.

A recorded zero means that the registry reports no affected participants in that specified field; it does not establish that no adverse experiences of any kind occurred. The counts also do not reveal how completely events were collected or whether all participants had the same period of observation. These safety entries do not supply evidence about comparative effectiveness, and should not be interpreted as such.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a randomized, parallel-group comparison of telepsychology and face-to-face therapy was conducted and completed. It describes the intended primary endpoint as the proportion with at least a 50% improvement on the GDS from baseline to post-treatment, with assessments listed at 8 week & 12 months. It also documents the intended service-delivery distinction: therapy at the patient's house by telepsychology versus therapy at the VAMC in person.

The record does not report the primary response proportions, confidence intervals, or an arm-to-arm comparison. It explicitly says the primary outcome has several categories or time points and was not reduced to one comparison. As a result, the registry record cannot show whether the two groups' response rates differed, how large any difference was, or how precisely it was estimated. An absent comparison is not evidence of no difference and is not evidence that either approach was superior.

The registry's completed status does not fill this results gap. Completion indicates the study status recorded in the registry, not that outcome data or statistical analyses are available in this entry. The secondary SCID measure is named but its results are not recorded. There is also no reported account of acceptability results, despite acceptability being part of the study's stated purpose.

More broadly, the record cannot establish whether any observed response would be attributable to the delivery format rather than other differences in treatment delivery or follow-up. Details about therapy content, missing assessments, outcome analysis, and masking of assessors are not reported in the registry record. Statistical interpretation requires those results and methods, not just the study objective and design. The defensible reading is therefore limited: the registry documents the comparison and endpoint, but does not provide enough outcome information to determine what the trial found.

13. Why This Trial Matters Statistically

This trial addresses a statistical question that is distinct from whether therapy itself is beneficial: whether a service-delivery approach using videoconferencing can be compared with face-to-face delivery on a specified response outcome. Randomization and a parallel-group structure are relevant to such a comparison, while the open-label design and self-report endpoint make the details of outcome collection and analysis important to interpretation.

The endpoint illustrates a common trade-off in clinical research. A threshold-based responder outcome gives a compact description of whether a participant met a stated improvement criterion, but compresses a graded scale into two categories. That makes the definition and reporting of both the threshold and the follow-up time essential. This record gives the threshold and lists follow-up times, but does not give the outcome estimates needed to evaluate the comparison.

It also illustrates why study completion and result availability are different. A registry may document a trial's design, intended endpoint, and status without reporting an analyzable result. Here, the primary outcome is explicitly not reduced to one comparison, and the analysis count is recorded as 0. Without estimates and uncertainty intervals, readers cannot assess the direction, size, or precision of the result. The record therefore highlights the value of complete, time-specific reporting alongside design information.

Finally, the delivery context makes clear that a statistical contrast must be interpreted in relation to what was actually compared. The registry describes treatment at home by telepsychology and treatment at the VAMC face-to-face, but provides limited detail about other treatment components. This record can frame the research question and explain the endpoint, but cannot support a conclusion about the comparative outcome.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting this trial from the registry record is the absence of an analyzable primary-outcome comparison. The response estimates and their 95% confidence intervals are not reported. The record itself notes multiple categories or time points and that the outcome was not reduced to one comparison. The direction, magnitude, and precision of any difference therefore remain unknown in this record.

The endpoint is described for participants completing assessments at 8 week and 12 months, but the number with outcome data at each time point and the handling of incomplete follow-up are not reported. The record does not identify the analysis population or missing-data method. This limits assessment of whether the outcome population reflects the randomized groups and how missing observations may affect the percentages.

Important methods are also not reported in the registry record: allocation concealment, the randomization procedure, whether assessors were masked, the statistical analysis plan, and any adjustment for multiple time points or outcomes. The registry does not give the rationale for the response threshold, score-handling details, treatment adherence, or information about therapy content and fidelity. These omissions do not prove that the methods were inadequate; they restrict what can be assessed using this record.

The stated objective includes acceptability, but the registry entry does not provide acceptability results. It lists SCID as a secondary outcome without reporting its results. Safety fields record zero affected participants for the listed serious and other adverse-event categories, while deaths are null; the record does not provide further event definitions or collection details. Together, these gaps mean the registry entry offers a limited account of the trial's outcomes and conduct.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Telepsychology-Service Delivery for Depressed Elderly Veterans — NCT00324701.
• Registry record last updated 2015-04-24; status last verified 2014-09.
• Results first posted 2014-11-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00324701 is a completed randomized, parallel-group trial with no masking, sponsored by the US Department of Veterans Affairs. It compares telepsychology delivered at patients' houses with face-to-face therapy delivered at the VAMC. The recorded enrollment is 241; the study start is listed as 2006-09 and primary completion as 2011-07.

The primary endpoint is at least a 50% improvement from baseline to post-treatment on the GDS, with 8 week & 12 months listed as the timeframe. The registry record describes the endpoint but does not report a single analyzable comparison or outcome estimates. SCID is listed as a secondary outcome, with no result reported. The record lists 0 analyses. Serious and other adverse-event counts are recorded as 0 in both groups; death counts are null.